336 related articles for article (PubMed ID: 9316840)
1. The orally active ET(A) receptor antagonist (+)-(S)-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphe nyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats.
Prié S; Leung TK; Cernacek P; Ryan JW; Dupuis J
J Pharmacol Exp Ther; 1997 Sep; 282(3):1312-8. PubMed ID: 9316840
[TBL] [Abstract][Full Text] [Related]
2. Activation of the right ventricular endothelin (ET) system in the monocrotaline model of pulmonary hypertension: response to chronic ETA receptor blockade.
Jasmin JF; Cernacek P; Dupuis J
Clin Sci (Lond); 2003 Dec; 105(6):647-53. PubMed ID: 12823096
[TBL] [Abstract][Full Text] [Related]
3. EndothelinA receptor blockade improves nitric oxide-mediated vasodilation in monocrotaline-induced pulmonary hypertension.
Prié S; Stewart DJ; Dupuis J
Circulation; 1998 Jun; 97(21):2169-74. PubMed ID: 9626178
[TBL] [Abstract][Full Text] [Related]
4. Genistein, a phytoestrogen, attenuates monocrotaline-induced pulmonary hypertension.
Homma N; Morio Y; Takahashi H; Yamamoto A; Suzuki T; Sato K; Muramatsu M; Fukuchi Y
Respiration; 2006; 73(1):105-12. PubMed ID: 16432296
[TBL] [Abstract][Full Text] [Related]
5. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats.
Hill NS; Warburton RR; Pietras L; Klinger JR
J Appl Physiol (1985); 1997 Oct; 83(4):1209-15. PubMed ID: 9338430
[TBL] [Abstract][Full Text] [Related]
6. Defective intracellular calcium handling in monocrotaline-induced right ventricular hypertrophy: protective effect of long-term endothelin-A receptor blockade with 2-benzo[1,3]dioxol-5-yl-3-benzyl-4-(4-methoxy-phenyl-)- 4-oxobut-2-enoate-sodium (PD 155080).
Brunner F; Wölkart G; Haleen S
J Pharmacol Exp Ther; 2002 Feb; 300(2):442-9. PubMed ID: 11805203
[TBL] [Abstract][Full Text] [Related]
7. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS
Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of a nonselective ET(A/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension.
Jasmin JF; Lucas M; Cernacek P; Dupuis J
Circulation; 2001 Jan; 103(2):314-8. PubMed ID: 11208695
[TBL] [Abstract][Full Text] [Related]
9. Short-term administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy.
Jasmin JF; Mercier I; Dupuis J; Tanowitz HB; Lisanti MP
Circulation; 2006 Aug; 114(9):912-20. PubMed ID: 16940204
[TBL] [Abstract][Full Text] [Related]
10. The orally active nonpeptide selective endothelin ETA receptor antagonist YM598 prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats.
Yuyama H; Fujimori A; Sanagi M; Koakutsu A; Sudoh K; Sasamata M; Miyata K
Eur J Pharmacol; 2004 Aug; 496(1-3):129-39. PubMed ID: 15288584
[TBL] [Abstract][Full Text] [Related]
11. Endothelial nitric oxide synthase-enhancing G-protein coupled receptor antagonist inhibits pulmonary artery hypertension by endothelin-1-dependent and endothelin-1-independent pathways in a monocrotaline model.
Liu CP; Dai ZK; Huang CH; Yeh JL; Wu BN; Wu JR; Chen IJ
Kaohsiung J Med Sci; 2014 Jun; 30(6):267-78. PubMed ID: 24835346
[TBL] [Abstract][Full Text] [Related]
12. Preventive effects of raloxifene, a selective estrogen receptor modulator, on monocrotaline-induced pulmonary hypertension in intact and ovariectomized female rats.
Nishida M; Hasegawa Y; Tanida I; Nakagawa E; Inaji H; Ohkita M; Matsumura Y
Eur J Pharmacol; 2009 Jul; 614(1-3):70-6. PubMed ID: 19379725
[TBL] [Abstract][Full Text] [Related]
13. The ET(A)-Receptor Antagonist LU 135252 Prevents the Progression of Established Pulmonary Hypertension Induced by Monocrotaline in Rats.
Dupuis J; Prié S
J Cardiovasc Pharmacol Ther; 1999 Jan; 4(1):33-39. PubMed ID: 10684522
[TBL] [Abstract][Full Text] [Related]
14. PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats.
Porvasnik SL; Germain S; Embury J; Gannon KS; Jacques V; Murray J; Byrne BJ; Shacham S; Al-Mousily F
J Pharmacol Exp Ther; 2010 Aug; 334(2):364-72. PubMed ID: 20430844
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effects of γ-aminobutyric acid on right ventricular pressure and pulmonary vascular remodeling in experimental pulmonary hypertension.
Suzuki R; Maehara R; Kobuchi S; Tanaka R; Ohkita M; Matsumura Y
Life Sci; 2012 Oct; 91(13-14):693-8. PubMed ID: 22542556
[TBL] [Abstract][Full Text] [Related]
16. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist.
Tilton RG; Munsch CL; Sherwood SJ; Chen SJ; Chen YF; Wu C; Block N; Dixon RA; Brock TA
Pulm Pharmacol Ther; 2000; 13(2):87-97. PubMed ID: 10799286
[TBL] [Abstract][Full Text] [Related]
17. A novel ACE2 activator reduces monocrotaline-induced pulmonary hypertension by suppressing the JAK/STAT and TGF-β cascades with restored caveolin-1 expression.
Haga S; Tsuchiya H; Hirai T; Hamano T; Mimori A; Ishizaka Y
Exp Lung Res; 2015 Feb; 41(1):21-31. PubMed ID: 25275723
[TBL] [Abstract][Full Text] [Related]
18. Salvia Miltiorrhiza Bge.f.alba Ameliorates the Progression of Monocrotaline-Induced Pulmonary Hypertension by Protecting Endothelial Injury in Rats.
Wang Y; Cao SH; Cui YJ; Kong LK; Tian H; Cai HX; Wu YP; Han JJ; Zhao XM; Xia ZL
Tohoku J Exp Med; 2015 Jun; 236(2):155-62. PubMed ID: 26074502
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline.
Voelkel NF; Tuder RM; Bridges J; Arend WP
Am J Respir Cell Mol Biol; 1994 Dec; 11(6):664-75. PubMed ID: 7946395
[TBL] [Abstract][Full Text] [Related]
20. Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in rats.
Sun X; Ku DD
Am J Physiol Heart Circ Physiol; 2008 Feb; 294(2):H801-9. PubMed ID: 18055512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
